A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea

Summary

The primary objective of this study is to evaluate the efficacy and safety of KHK4827 in subjects with moderate to severe plaque psoriasis randomized in a double-blind manner to receive KHK4827 or placebo for 12 weeks

Timeline

Start

2017-01

Primary completion

2018-08-14

Completion

2018-08-14

Drugs

Indications